1. Home
  2. AMAL vs EVO Comparison

AMAL vs EVO Comparison

Compare AMAL & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amalgamated Financial Corp. (DE)

AMAL

Amalgamated Financial Corp. (DE)

HOLD

Current Price

$40.47

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.76

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMAL
EVO
Founded
1923
1993
Country
United States
Germany
Employees
450
4553
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
934.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
AMAL
EVO
Price
$40.47
$2.76
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
$36.00
$7.00
AVG Volume (30 Days)
115.8K
95.9K
Earning Date
04-23-2026
04-08-2026
Dividend Yield
1.68%
N/A
EPS Growth
N/A
N/A
EPS
0.84
N/A
Revenue
N/A
N/A
Revenue This Year
$21.18
$1.37
Revenue Next Year
$6.55
$10.05
P/E Ratio
$47.26
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.13
$2.31
52 Week High
$44.01
$4.80

Technical Indicators

Market Signals
Indicator
AMAL
EVO
Relative Strength Index (RSI) 47.91 41.07
Support Level $36.50 $2.32
Resistance Level $40.89 $3.78
Average True Range (ATR) 1.07 0.09
MACD -0.23 -0.06
Stochastic Oscillator 32.02 19.16

Price Performance

Historical Comparison
AMAL
EVO

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: